Real-world experience with ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin in HCV infection

被引：19
|
作者：
Pogorzelska, Joanna [1 ]
Flisiak, Robert [1 ]
机构：
[1] Med Univ Bialystok, Dept Infect Dis & Hepatol, 14 Zurawia St, PL-15540 Bialystok, Poland
来源：
CLINICAL AND EXPERIMENTAL HEPATOLOGY | 2016年 / 2卷 / 02期
关键词：
HCV; paritaprevir; ombitasvir; dasabuvir;
D O I：
10.5114/ceh.2016.60247
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Ombitasvir/paritaprevir boosted with ritonavir and possibly combined with dasabuvir and ribavirin (OBV/PTV/r +/- DSV +/- RBV) is a new direct-acting antiviral (DAA) regimen which has improved efficacy of chronic hepatitis C virus (HCV) treatment significantly. OBV/PTV/r +/- DSV +/- RBV in clinical trials demonstrated sustained viral response (SVR) rates close to 100%. In this article we collected currently available data of 5726 patients for evaluation of OBV/PTV/r +/- DSV +/- RBV efficacy and safety in real-world experience. The sustained viral response rate in this large population was 97%, and it was exactly the same even in patients with liver cirrhotics. According to this meta-analysis, less than 3% of patients discontinued treatment due to adverse events.
引用
收藏
页码：34 / 37
页数：4
相关论文
共 50 条
  • [41] Real-life data on the efficacy and safety of ombitasvir/paritaprevir//ritonavir plus dasabuvir plus ribavirin in the patients with genotype 1 chronic hepatitis C virus infection in Serbia
    Babic, Jasmina Simonovic
    Bojovic, Ksenija
    Fabri, Milotka
    Cvejic, Tatjana
    Svorcan, Petar
    Nozic, Darko
    Jovanovic, Maja
    Skrbic, Ranko
    Stojiljkovic, Milos P.
    Mijailovic, Zeljko
    VOJNOSANITETSKI PREGLED, 2019, 76 (05) : 531 - 536
  • [42] Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
    Perello, C.
    Carrion, J. A.
    Ruiz-Antoran, B.
    Crespo, J.
    Turnes, J.
    Llaneras, J.
    Lens, S.
    Delgado, M.
    Garcia-Samaniego, J.
    Garcia-Paredes, F.
    Fernandez, I.
    Morillas, R. M.
    Rincon, D.
    Porres, J. C.
    Prieto, M.
    Lazaro Rios, M.
    Fernandez-Rodriguez, C.
    Hermo, J. A.
    Rodriguez, M.
    Herrero, J. I.
    Ruiz, P.
    Fernandez, J. R.
    Macias, M.
    Pascasio, J. M.
    Moreno, J. M.
    Serra, M. A.
    Arenas, J.
    Real, Y.
    Jorquera, F.
    Calleja, J. L.
    JOURNAL OF VIRAL HEPATITIS, 2017, 24 (03) : 226 - 237
  • [43] Eight weeks of Paritaprevir/r/Ombitasvir plus Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
    Puigvehi, Marc
    De Cuenca, Beatriz
    Viu, Ana
    Diago, Moises
    Turnes, Juan
    Gea, Francisco
    Pascasio, Juan M.
    Lens, Sabela
    Cabezas, Joaquin
    Badia, Ester
    Olveira, Antonio
    Morillas, Rosa M.
    Torras, Xavier
    Montoliu, Silvia
    Cordero, Patricia
    Castro, Jose L.
    Salmeron, Javier
    Molina, Esther
    Sanchez-Ruano, Juan J.
    Moreno, Javier
    Anton, Maria D.
    Moreno, Jose M.
    De la Vega, Juan
    Calleja, Jose L.
    Carrion, Jose A.
    LIVER INTERNATIONAL, 2019, 39 (01) : 90 - 97
  • [44] Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
    Liat Deutsch
    Inbal Houri
    Ziv Ben-Ari
    Amir Shlomai
    Ella Veitsman
    Oranit Cohen-Ezra
    Assaf Issachar
    Orna Mor
    Yael Gozlan
    Rafael Bruck
    Yoram Menachem
    Shira Zelber-Sagi
    Helena Katchman
    Oren Shibolet
    BMC Infectious Diseases, 20
  • [45] Paritaprevir/ritonavir/ombitasvir plus dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report
    Puglisi, G. M.
    Smith, S. M.
    Jankovich, R. D.
    Ashby, C. R.
    Jodlowski, T. Z.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (01) : 115 - 118
  • [46] Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials
    Mensing, Sven
    Eckert, Doerthe
    Sharma, Shringi
    Polepally, Akshanth R.
    Khatri, Amit
    Podsadecki, Thomas J.
    Awni, Walid M.
    Menon, Rajeev M.
    Dutta, Sandeep
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (03) : 527 - 539
  • [47] Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection
    Smith, Michael A.
    Lim, Alice
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6083 - 6094
  • [48] Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports
    Ponziani, Francesca Romana
    Siciliano, Massimo
    Lionetti, Raffaella
    Pasquazzi, Caterina
    Gianserra, Laura
    D'Offizi, Gianpiero
    Gasbarrini, Antonio
    Pompili, Maurizio
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2017, 70 (02) : 297 - 300
  • [49] Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents
    Shiffman, Mitchell L.
    Rustgi, Vinod
    Bennett, Michael
    Forns, Xavier
    Asselah, Tarik
    Vila, Ramon Planas
    Liu, Li
    Pedrosa, Marcos
    Moller, Jonathan
    Reau, Nancy
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2016, 111 (06) : 845 - 851
  • [50] Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis
    Chen, Chun-Hsien
    Chen, Chien-Hung
    Lin, Chih-Lang
    Lin, Chun-Yen
    Hu, Tsung-Hui
    Tung, Shui-Yi
    Hsieh, Sen-Yung
    Lu, Sheng-Nan
    Chien, Rong-Nan
    Hung, Chao-Hung
    Sheen, I-Shyan
    SCIENTIFIC REPORTS, 2019, 9 (1)
12345